Arcutis Biotherapeutics, Inc.
ARQT
주식 순위
#4008
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
주가
$32.29
마지막 동기화: 2026-10-19
시가총액
$4.06B
변동 (1일)
12.02%
변동 (1년)
54.62%
국가
US
거래 Arcutis Biotherapeutics, Inc. (ARQT)
카테고리
Healthcare
Arcutis Biotherapeutics, Inc. (ARQT)의 P/B 비율
October 2026 기준 P/B 비율 TTM: 15.63
Arcutis Biotherapeutics, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 15.63입니다. 2023년 말 기준 P/B 비율은 2.52였습니다.
Arcutis Biotherapeutics, Inc.의 P/B 비율 기록 (2017 ~ 2026)
매년 말 P/B 비율
| 연도 | P/B 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 15.63 | 46.05% |
| 2024 | 10.70 | 323.63% |
| 2023 | 2.52 | -35.03% |
| 2022 | 3.89 | 12.90% |
| 2021 | 3.44 | -7.15% |
| 2020 | 3.71 | -129.04% |
| 2019 | -12.77 | -61.23% |
| 2018 | -32.93 | 614.27% |
| 2017 | -4.61 | 0.00% |
유사 기업 또는 경쟁사의 P/B 비율
| 회사 | P/B 비율 | P/B 비율 차이 | 국가 |
|---|---|---|---|
| 6.251 | -60.00% |
US
|
|
| 13.2547 | -15.18% |
US
|
|
| 4.208 | -73.07% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -60.44% |
NL
|
